TNR: Early RA - Referrals and Treatment

Save

This Tuesday Night Rheumatology was an hour long panel discussion featuring Drs. Jack Cush, Vivian Bykerk, Glen Hazelwood and Martin J. Bergman. The​ Panel discussed Rheumatologists ​views on Early RA referral and intake, initial treatment preferences and views on diagnosing and treating pre-clinical RA.

RA Extra-articular Manifestations Declining

Save

A Mayo Clinic population based cohort study shows the extraarticular manifestations of rheumatoid arthritis (ExRA) have declined with time; but the increased mortality risk of RA remains unchanged.

Hydroxychloroquine Adherence Lowers Cardiovascular Risks

Save

Daily hydroxychloroquine (HCQ) is better than an apple a day; as a new study shows that adherence to the antimalarial agent significantly lowers future risk of cardiovascular events in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.

RheumNow Podcast – with Special Guest Dr. Janet Pope (9.8.2023)

Save

This week, Dr. Jack Cush reviews the news with special guest, Dr. Janet Pope. They discuss "Not-non-Inferior", large scale genetic screening, Zoster risk w/ newer lupus drugs, tapering, RA referral problems and the TNR webinar session on "ORAL Surveillance Revisited".

Woeful Rheumatology Referrals

Save

Early diagnosis of inflammatory arthritis (IA) is rooted in patient (self or MD) referrals. A recent analysis shows only a minority of rheumatology referrals had inflammatory arthritis, with only 21% were seen within the first 6 weeks of symptoms. 

Oral Surveillance Changes in Advanced Therapy Use in RA

Save

The safety of tofacitinib and TNF inhibitors was studied in high risk rheumatoid arthritis (RA) patients in the ORAL Surveillance study, which culminated in an FDA warning in January 2021 on the cardiovascular, cancer and VTE risks associated with JAK inhibitor use.

Aortic Stenosis Risk in RA

Save

A large cohort study has shown that rheumatoid arthritis (RA) patients are at an increased risk of developing aortic stenosis (AS), undergoing aortic valve intervention, or AS-related death.

ICYMI: ACR Guidelines for Interstitial Lung Disease in Patients with Rheumatic Conditions

Save

The American College of Rheumatology released summaries of two new guidelines for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease and for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.

Hard Decisions in RA (9.1.2023)

Save

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

ACR Position Paper: Cost Impact of Rheumatologic Care

Save

The American College of Rheumatology (ACR) has published evidence that rheumatologic care can save more than $2700 per patient per year.

FDA Approves Canakinumab for Gout Flares

Save

The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) for the treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine, or repeated courses of corticosteroids. The drug is also indicated for people who could not tolerate or had an inadequate response to NSAIDs or colchicine.

SGLT2 Inhibitors as Gout Treatment

Save

Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, researchers said.